Alternative Data for Halozyme Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 6 | Sign up | Sign up | Sign up |
| Sentiment | 86 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 32 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,938 | Sign up | Sign up | Sign up |
| X Followers | 684 | Sign up | Sign up | Sign up |
| X Mentions | 31 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 76 | Sign up | Sign up | Sign up |
| Linkedin Employees | 528 | Sign up | Sign up | Sign up |
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
| Price | $70.03 |
| Target Price | Sign up |
| Volume | 2,923,099 |
| Market Cap | $7.87B |
| Year Range | $61.63 - $81.23 |
| Dividend Yield | 0% |
| PE Ratio | 25.94 |
| Analyst Rating | 43% buy |
| Industry | Biotechnology |
In the news
 |
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCEMay 11 - PRNewswire |
Halozyme (HALO) Rated Buy on Strong Royalty GrowthMay 2 - Yahoo Entertainment |
|
Halozyme Therapeutics (HALO) Appoints Interim CFO Amid Growth PlansMarch 29 - Yahoo Entertainment |
|
 |
2 Reasons to Like HALO (and 1 Not So Much)February 24 - Yahoo |
Benchmark Maintains Buy on Halozyme Therapeutics, Raises Price Target to $90February 18 - Benzinga |
|
|
Halozyme (HALO) Loses 9% on Weak EarningsFebruary 18 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 452M | 102M | 350M | -142M | 281M | -0.240 |
| Q3 '25 | 354M | 55M | 299M | 175M | 285M | 1.720 |
| Q2 '25 | 326M | 46M | 279M | 165M | 230M | 1.540 |
| Q1 '25 | 265M | 48M | 216M | 118M | 169M | 1.110 |
| Q4 '24 | 298M | 42M | 256M | 137M | 203M | 1.260 |
Insider Transactions View All
| Connaughton Bernadette filed to sell 38,498 shares at $63.5. May 5 '26 |
| Torley Helen filed to sell 767,780 shares at $64. April 7 '26 |
| Torley Helen filed to sell 771,880 shares at $63.1. April 7 '26 |
| Torley Helen filed to sell 767,780 shares at $64.9. April 2 '26 |
| Torley Helen filed to sell 771,980 shares at $64.1. April 2 '26 |
Similar companies
Read more about Halozyme Therapeutics (HALO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Halozyme Therapeutics
The Market Cap of Halozyme Therapeutics is $7.87B.
As of today, Halozyme Therapeutics' PE (Price to Earnings) ratio is 25.94.
Currently, the price of one share of Halozyme Therapeutics stock is $70.03.
The HALO stock price chart above provides a comprehensive visual representation of Halozyme Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Halozyme Therapeutics shares. Our platform offers an up-to-date HALO stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Halozyme Therapeutics (HALO) does not offer dividends to its shareholders. Investors interested in Halozyme Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Halozyme Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
